Aquestive Therapeutics heads into today's earnings print with options traders at their most defensive in a year, even as short sellers show early signs of pulling back.
The options market is sending the loudest pre-earnings signal. The put/call ratio has climbed to 1.295 — more than two standard deviations above its 20-day average of 0.88 — and is sitting just below its 52-week high of 1.35. That's a sharp reversal from mid-July, when the PCR was running below 0.4. The rotation into puts has accelerated over the past week in lockstep with an 18% price rally to $4.41, suggesting options traders are paying up for downside protection against a stock that has moved quickly. The two most recent earnings events are consistent with that caution: AQST rose roughly 9% on the day after its August 2025 print, and 5.5% after its June 2025 event (with a further 11% gain over the following five days), so the history of meaningful moves adds to the demand for hedges.
Short interest tells a less aggressive story heading in. Bears hold 13.6% of the free float short — a genuinely elevated level — but that position has been essentially flat over the past week and has edged down over the past two sessions. Borrow availability has loosened materially, jumping from under 8% last week to 25% now, meaning the lending market has freed up substantially after a spell of near-maximum tightness earlier in August. Cost to borrow is modest at around 1.1%. Together, these point to a short base that is holding its position but not adding conviction ahead of the print.
The bull and bear debate centres on Anaphylm, AQST's no-needle epinephrine candidate. Bulls point to the FDA declining to convene an Advisory Committee for the NDA — a signal the agency is comfortable with the data package — and a wall of analyst buy ratings, with consensus targets clustering around $9, roughly double the current price. Bears counter that the company's financial position remains fragile: AQST is pre-profitability, all valuation multiples are negative, and any setback to the pipeline raises real capital-raise questions. Analyst activity has been quiet in recent months; the last meaningful moves — Piper Sandler lifting to $8 and JMP Securities raising to $12 — both date from late 2025, leaving the targets well above the current price but increasingly stale.
Institutional flows add a nuanced layer. Several specialist healthcare funds built positions in Q1, with RTW Investments adding over 1.1 million shares and Balyasny initiating a 1.9-million-share stake. BlackRock and State Street also added in Q2. Against that, CEO Daniel Barber has been a consistent seller through May, June, and July at prices between $4.00 and $4.30 — modest in dollar terms but a steady directional signal. The print will test whether progress on Anaphylm's regulatory timeline is sufficient to narrow the gap between where management is selling and where the Street believes the stock belongs.
See the live data behind this article on ORTEX.
Open AQST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
